Influence of Initial Therapy on Outcome of Peptic Ulcer

Histamine 2 (H2) receptor antagonists, proton pump inhibitors, prostaglandin analogues, colloidal bismuth and sucralfate have all proved safe and effective in the initial treatment of peptic ulcer. Yet, most ulcers will recur when treatment is stopped. Continuous maintenance with H2 antagonists results in low symptomatic relapse, complications occur rarely, and such treatment is safe. An alternative is Symptomatic Self Care (on-demand therapy), which provides an economic option for patients with no concomitant disease or previous complications. Meta-analyses suggest a higher relapse rate after H2 antagonist therapy than that following sucralfate or bismuth. Whilst improved morphology and/or functional status of the gastro-duodenal mucosa ('quality of healing') has been claimed, the difference has not been explained. Successful prolonged eradication of Helicobacter pylori leads to a very low relapse rate, but more effective, predictable and safer eradication regimens are needed.